Health House International Ltd
ASX:HHI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (0.3), the stock would be worth AU$0.01 (0% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | AU$0.01 |
0%
|
| 3-Year Average | 0.3 | AU$0.01 |
0%
|
| 5-Year Average | 0.3 | AU$0.01 |
0%
|
| Industry Average | 3.1 | AU$0.05 |
+900%
|
| Country Average | 5.8 | AU$0.1 |
+1 802%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Health House International Ltd
ASX:HHI
|
891.1k AUD | 0.3 | -0.5 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.1B USD | 7.3 | 23.1 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.1B USD | 5.5 | 36.4 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.5B USD | 5.5 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
46.1B USD | 5.7 | 27.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.3B AUD | 13.9 | 35.5 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.4B CNY | 2.5 | 11.1 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 2.8 | 21.5 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.5B CNY | 5.1 | 20.6 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 19.4 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.6B HKD | 0.2 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 3.4 |
| Median | 5.8 |
| 70th Percentile | 11.1 |
| Max | 27 768.2 |
Other Multiples
Health House International Ltd
Glance View
Health House International Ltd. is an international distributor of medicinal cannabis. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-07-28. Its primary activities include operations in the pharmaceutical wholesale and distribution sectors. The company has two operating subsidiaries: Health House Pharma Limited, an international pharmaceutical distribution business in the United Kingdom and Health House International Pty Limited, a medicinal cannabis distribution business in Australia. Th products distributed by the Company include iX Biopharma’s Xativa, which is formulated using WaferiX, which is patented sublingual delivery technology, and Zelira Therapeutics’ cannabinoid-based customized medicines, including HOPE1, HOPE2 and Zenivol oil blended with pharmaceutical-grade sunflower oil. The company distributes Levin Health’s cannabinoid-based, chronic pain medicines, such as LEVIN CBD 100 and LEVIN Balance 10:12. The company also distributes products of various companies, such as Satipharm, HAPA pharm, Ananda Hemp and Little Green Pharma.
